United Therapeutics | UTHR - Sales Revenues

Stock Price
473.25
Daily Change
-1.27 -0.27%
Monthly
-0.02%
Yearly
32.38%
Q1 Forecast
458.74

United Therapeutics reported $799.5M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Amarin USD 49.67M 23.07M Sep/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Baxter International USD 2.97B 130M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Lexicon Pharmaceuticals USD 1.65M 520K Jun/2024
Moderna USD 678M 342M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025